Introduction

Thursday brought a fresh wave of research notes from Wall Street firms, with analysts adjusting ratings and price targets across technology, insurance, biotech, and industrial sectors. From artificial intelligence specialists to legacy hardware makers, the latest commentary offers a snapshot of where institutional investors see opportunity and risk heading into the end of the year.

What Happened

Several firms led with new coverage or rating changes on high-profile names. Wolfe initiated coverage of Anthropic with an outperform call, describing the AI company as best-in-class and highlighting its total addressable market and revenue trajectory. JPMorgan maintained its overweight stance on Apple, citing survey data that shows strong consumer interest in the upcoming iPhone cycle, particularly among existing users upgrading to Pro models.

UBS moved Box to a buy rating from neutral, pointing to AI-driven growth acceleration in enterprise content workflows. On the semiconductor side, Daiwa reiterated Nvidia as outperform but trimmed its price target to $185 from $245, while raising questions about peak AI capital spending and CEO succession. Morgan Stanley kept SpaceX at overweight, labeling it a top pick for portfolios tied to the so-called Resiliency Economy.

Other notable actions included Barclays initiating coverage on Synopsys, Vylor, and BBB Foods, all with overweight ratings. StoneX began coverage on NXP Semiconductors and Harley-Davidson with buy ratings. Bank of America initiated Viridian Therapeutics as a buy, and Oppenheimer started coverage on several smaller names, including Unusual Machines, HawkEye 360, and Swarmer, each with outperform ratings.

Insurance and healthcare names also saw movement. Leerink upgraded Abbott Labs to outperform from market perform, while UBS raised Unum Group and Reinsurance Group of America to buy. Citizens lifted Expeditors International to market outperform with a $240 price target, implying roughly 27% upside.

Why This Matters

Analyst ratings often influence short-term trading and can signal broader conviction about industry trends. The cluster of AI-related commentary spanning Anthropic, Box, Synopsys, and Nvidia suggests Wall Street is still sorting out which companies will capture the most value from artificial intelligence spending. Meanwhile, the mix of insurance upgrades and biotech initiations shows investors are rotating through defensive and growth-oriented pockets of the market.

Price target changes, such as the reduction for Nvidia and the hike for Reinsurance Group of America, provide concrete benchmarks for traders tracking valuation. Initiations on newer public companies like Vylor and BBB Foods also bring fresh visibility to stocks that may not yet have broad research coverage.

Key Takeaways

  • Wolfe initiated Anthropic as outperform, calling it a top AI business with strong revenue potential.
  • JPMorgan reiterated Apple as overweight, citing elevated purchase intent for the iPhone 18 cycle.
  • UBS upgraded Box to buy, citing AI-driven acceleration in software growth.
  • Daiwa kept Nvidia at outperform but lowered its price target to $185 per share.
  • Morgan Stanley maintained SpaceX as overweight and a best idea for resilience-focused portfolios.
  • Barclays started coverage on Synopsys, Vylor, and BBB Foods with overweight ratings.
  • Leerink upgraded Abbott Labs to outperform, seeing a more favorable risk/reward setup.
  • Monness Crespi Hardt downgraded Strategy to sell, citing concerns around Bitcoin exposure and leverage.

Conclusion

Thursday’s analyst calls paint a picture of a market still navigating the AI boom while reassessing traditional sectors like insurance and industrials. Investors should treat these ratings as one input among many, weighing price targets, firm track records, and their own investment horizons before making decisions. As always, individual ratings can shift quickly, especially in fast-moving areas like artificial intelligence and defense technology.